Corporate Updates-Hyperway Pharmaceutical Co.,Ltd.

Hyperway News

Hyperway News

>

2025-11-27
Hyperway Pharma Advances HBW-3220 Capsules into Phase III Clinical Trials

View more
2025-10-31
Another Milestone: Hyperway Pharma’s Pan-KRAS Inhibitor Secures NMPA Clinical Trial Approval

View more
2025-10-22
Hyperway Pharma Secures Over 200 Million CNY in Series B Funding

View more
2025-08-15
Hyperway Pharma Submits IND for Pan-KRAS Inhibitor HBW-012462

View more
2025-04-01
Hyperway Reaches New Milestone: HBW-012336 Oral KRAS G12D Inhibitor Gains Clinical Trial Approval

View more
2025-02-28
HBW-3220 Capsules Achieve 100% ORR, Offering New Hope for C481S Mutation Patients

View more
2025-01-31
Hyperway Pharma's HBW-004285 Shows Promise, Potentially Surpassing VX-548 in Clinical Trials

View more
2025-01-10
IND Submission for KRAS G12D Inhibitor Signals New Era in Cancer Research

View more

«
1
2
»